CML Partnership 09712

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.